Skip to content Skip to footer
Subscribe Now
WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Oct 13, 2025 – Oct 17, 2025)    

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, DigiHealth, Animal Health, and Biosimilars. Check out our full report below: Arcus Biosciences Reports the P-II (EDGE-Gastric) Trial Data on Domvanalimab + Yutuo (Zimberelimab) for Gastroesophageal Adenocarcinomas Read More: Arcus Biosciences HUTCHMED Reports the P-II/III (FRUSICA-2) Trial Data of Fruquintinib…
October 17, 2025

Read more

EXCLUSIVE

Exclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight 

Shots: Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably   NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research   In this exclusive conversation, Edmund…
October 14, 2025

Read more

NEWS

PharmaShots Weekly Snapshots (Oct 06, 2025 – Oct 10, 2025)   

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, DigiHealth, Animal Health, and Biosimilars. Check out our full report below:     AstraZeneca and Daiichi Sankyo Report P-III (TROPION-Breast02) Trial Results of Datroway for Triple-Negative Breast Cancer Read More: AstraZeneca and Daiichi Sankyo AstraZeneca Reports P-III (Bax24) Trial Data on…
October 10, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 29, 2025 – Oct 03, 2025)   

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health, and Biosimilars. Check out our full report below:   Daiichi Sankyo & AstraZeneca Report the Topline P-III (DESTINY-Breast05) Trial Data of Enhertu for High-Risk Early Breast Cancer Read More: Daiichi Sankyo & AstraZeneca Merck Presents P-III (HYPERION) Trial Data…
October 3, 2025

Read more

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2025 

Shots: Q3’25 was marked by major pharma and biotech M&A, led by BD’s $17.5B Reverse Morris Trust deal merging its Biosciences & Diagnostic Solutions unit with Waters, and Merck’s ~$10B acquisition of Verona Pharma The quarter spotlighted collaborations, notably GSK’s ~$12.5B agreement with Hengrui Pharma to co-develop up to 12 novel therapies across multiple disease areas. PharmaShots brings…
October 1, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 01, 2025 – Sep 05, 2025)   

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, COVID-19, Animal Health and Biosimilars. Check out our full report below:   Merck Reports P-III (VICTOR) Trial Data of Verquvo (Vericiguat) for Chronic Heart Failure and Reduced Ejection Fraction (HFrEF) Read More: Merck AstraZeneca Reports P-III (BaxHTN) Trial Data on Baxdrostat…
September 5, 2025

Read more

Load more